Financials

  • Market Capitalization 139.97 M
  • Employee 34
  • Founded 2004
  • CEO Christopher U. Missling Ph.D.
  • Website www.anavex.com
  • Headquarter New York, United States
  • FIGI BBG000C9K8K4
  • Industry Biotecnologia
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-16.48
Rapporto prezzo/fatturato
174.66

Related tickers

#NomePrezzo24h %7d %1M %1Y %Valore di MercatoUltimi 7 Giorni
3702
OTLK
Outlook Therapeutics, Inc. - Common Stock
0.59 USD-1.67%-1.67%-9.23%+43.03%143.63 M USD
3710
RNA
Atrium Therapeutics, Inc. - Common Stock
8.21 USD-2.26%+2.63%-20.83%-88.33%140.44 M USD
3713
VYGR
Voyager Therapeutics, Inc. - Common Stock
2.27 USD-7.35%-7.72%-28.39%-51.18%139.87 M USD
3718
IPHA
Innate Pharma S.A. - American Depositary Shares
1.48 USD-8.64%-6.33%-20.43%-31.48%138.70 M USD

Notizie